Big healthcare challenges demand cutting-edge healthcare products. Today's guest is building strategic partnerships to get ahead of disease and fuel the growth of their company. 

Today we're sitting down with Chris Hall, CEO and President of Personalis, which trades under the symbol PSNL. In his role, Chris drives the vision and strategy for the company, including commercializing its diagnostic product offerings. He brings over 20 years of experience in general management and product development within the diagnostics industry, most recently as CEO of Naring Health. 

Previously he served as President, COO, and Chief Commercial Officer of Veracyte Inc, where he led the company's commercial entry into endocrinology and pulmonology and scaled its operational groups. Chris also served as an SVP and Chief Business Officer at Berkeley HeartLab, part of Celera Corporation, where he helped new product launches, and restructured operations to improve profitability and streamline delivery of services.

Chris holds a BA in political science from DePauw University and an MBA from Harvard.

Highlights:

• Chris describes Personalis and their work (3:45)
• Personalis' MRD test and how it works (6:25)
• Chris walks us through Personalis' tech evolution (8:23)
• Personalis' current partnerships and collaborations (10:24)
• More about the internal team at Personalis (14:31)
• Chris discusses Personalis' recent Medicare coverage announcement (16:09) 
• The current macro environment's effect on business (18:09)
• 2023 highlights at Personalis (19:54)
• Near-future growth and development goals for Personalis (22:25)
• Leadership and company culture at Personalis (24:22)
• Product development and long-term objectives (26:19)

Links:

Chris Hall on LinkedIn

Personalis on LinkedIn

Personalis Website

ICR LinkedIn

ICR Twitter

ICR Website

Feedback:

If you have questions about the show, or have a topic in mind you'd like discussed in future episodes, email our producer, marion@lowerstreet.co.